Posts tagged Maxim Group


Promising Future For Omeros Corporation (OMER) with Lead Drug Omidria?

Drug maker Omeros Corporation (NASDAQ:OMER) delivered solid results for its earnings report for the first quarter of …

Gilead Sciences, Inc. (GILD) Under Pressure After Disappointing Q1 Earnings Report; Maxim Weighs In

Days are becoming tough for Gilead Sciences, Inc. (NASDAQ:GILD) as it recently released its 1Q17 …

4Q Update: Sophiris Bio Inc (SPHS) Gets A Buy From Maxim

Maxim analyst Jason Kolbert was out with a research note on Sophiris Bio Inc (NASDAQ:SPHS), following the …

Maxim Weighs in on Mast Therapeutics Inc (MSTX) Following Delay in EPIC Trial Data Results for SCD

Maxim analyst Jason McCarthy comments on Mast Therapeutics Inc (NYSEMKT:MSTX) ahead of EPIC study data …

Maxim Reiterates Buy on Juno Therapeutics Inc as FDA Lifts Clinical Hold on ROCKET

In a research report released today, Maxim analyst Jason McCarthy reiterated a Buy rating on …

Meeting With Management Causes Maxim Group To Cut Price Target for Galena Biopharma Inc (GALE)

Analyst Jason McCarthy of Maxim Group maintained a Buy rating for Galena Biopharma Inc (NASDAQ:GALE), but decreased his …

Analysts Shine Light On AEterna Zentaris Inc. (USA) (AEZS) And OraSure Technologies, Inc. (OSUR) Following Recent Developments

Healthcare analysts explain their bullish views on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) and OraSure Technologies, …

Maxim Weighs In on Anavex Life Sciences Corp. (AVXL), Pluristem Therapeutics Inc. (PSTI) Following Orphan Designation and Preclinical Data

Maxim’s healthcare analyst Jason Kolbert weighed in today on two names in his coverage universe, Anavex Life Sciences Corp. …

Hold the Phone on Biotech: Valeant Pharmaceuticals Intl Inc (VRX) and Gilead Sciences, Inc. (GILD)

While Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Gilead Sciences, Inc. (NASDAQ:GILD) remain biotech giants, they …

Biotech Beat: Analysts Weigh In on Exelixis, Inc. (EXEL) and Mast Therapeutics Inc (MSTX)

There’s good news all around as Exelixis, Inc. (NASDAQ:EXEL) releases promising data in an attempt …